These differences were largely driven by KRAS G12D mutants, aside from CTLA-4, whose decreased mRNA expression was found to be borderline significant ( Figure 6 ).
← all excerpts
Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to <i>KRAS</i> mutational status.
1
—
—